BCTXL — BriaCell Therapeutics Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1610820 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | 0 | -7,620,794 | -7,164,507 | 27,071,310 | 6,880,221 | 3,662,350 |
| Oct 2025 | 0 | 0 | -8,322,943 | -8,197,565 | 13,075,050 | 2,714,012 | 3,724,646 |
| Apr 2025 | 0 | 0 | -6,328,255 | -6,126,902 | 17,001,798 | 12,460,253 | 5,060,645 |
| Jan 2025 | 0 | 0 | -7,169,443 | -6,291,420 | 9,363,567 | 5,013,654 | 6,136,676 |
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jul 2025 | 0 | -27,204,803 | -26,311,867 | 21,649,706 | 4,315,660 | 17,334,046 | — |
| Jul 2024 | 0 | -33,330,076 | -4,791,466 | 5,872,261 | 8,557,193 | -2,684,932 | — |
| Jul 2023 | 2,209,061 | -23,272,264 | -20,302,394 | 27,163,577 | 30,940,758 | -3,777,181 | — |
| Jul 2022 | 3,090,835 | -15,288,941 | -26,838,903 | 42,577,041 | 32,248,109 | 10,328,932 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$27,071,310
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.04T | $1169.60 | — |
| JNJ | JOHNSON & JOHNSON | $618.09B | $256.48 | — |
| ABBV | AbbVie Inc. | $481.40B | $272.42 | — |
| MRK | Merck & Co., Inc. | $351.28B | $142.38 | — |
| NVS | NOVARTIS AG | $272.01B | $143.11 | — |
News headlines (Yahoo Finance, 1h cache)
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
2026-05-12 11:30 · Yahoo
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
2026-10-06 11:30 · Yahoo
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
2026-09-14 11:30 · Yahoo
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
2026-09-08 11:30 · Yahoo
BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone
2026-08-24 12:47 · Yahoo
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
2026-08-24 11:30 · Yahoo
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
2026-08-05 11:30 · Yahoo
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
2026-07-07 11:30 · Yahoo
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting
2026-06-01 13:57 · Yahoo
BriaCell Presents Positive Clinical Data at ASCO 2026
2026-06-01 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.